Dr. David Ivy, MD

NPI: 1083799712
Total Payments
$44,137
2024 Payments
$6,564
Companies
7
Transactions
41

Payment Breakdown by Category

Travel$22,935 (52.0%)
Consulting$19,965 (45.2%)
Food & Beverage$1,238 (2.8%)

Payments by Nature

Nature of Payment Amount Transactions Share
Travel and Lodging $22,935 10 52.0%
Consulting Fee $19,965 11 45.2%
Food and Beverage $1,238 20 2.8%

Top Paying Companies

Company Total Records Latest Year
Bayer HealthCare Pharmaceuticals Inc. $14,586 4 $0 (2020)
Merck Sharp & Dohme LLC $13,759 14 $0 (2024)
Actelion Pharmaceuticals, Ltd $11,221 5 $0 (2019)
Janssen Research & Development, LLC $2,100 2 $0 (2019)
Actelion Pharmaceuticals US, Inc. $1,574 12 $0 (2024)
Actelion Clinical Research, Inc. $600.00 1 $0 (2018)
United Therapeutics Corporation $297.42 3 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2024 $6,564 6 Merck Sharp & Dohme LLC ($6,540)
2023 $7,219 9 Merck Sharp & Dohme LLC ($7,219)
2020 $1,290 1 Bayer HealthCare Pharmaceuticals Inc. ($1,290)
2019 $13,321 7 Actelion Pharmaceuticals, Ltd ($11,221)
2018 $14,193 7 Bayer HealthCare Pharmaceuticals Inc. ($13,296)
2017 $1,550 11 Actelion Pharmaceuticals US, Inc. ($1,550)

All Payment Transactions

41 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
09/25/2024 Merck Sharp & Dohme LLC WINREVAIR (Biological) Consulting Fee Cash or cash equivalent $545.00 General
Category: CARDIOVASCULAR
09/04/2024 Actelion Pharmaceuticals US, Inc. UPTRAVI (Drug) Food and Beverage In-kind items and services $23.59 General
Category: Cardiology
05/08/2024 Merck Sharp & Dohme LLC WINREVAIR (Biological) Consulting Fee Cash or cash equivalent $545.00 General
Category: CARDIOVASCULAR
05/08/2024 Merck Sharp & Dohme LLC WINREVAIR (Biological) Consulting Fee Cash or cash equivalent $545.00 General
Category: CARDIOVASCULAR
03/11/2024 Merck Sharp & Dohme LLC WINREVAIR (Biological) Consulting Fee Cash or cash equivalent $545.00 General
Category: CARDIOVASCULAR
01/15/2024 Merck Sharp & Dohme LLC WINREVAIR (Biological) Consulting Fee Cash or cash equivalent $4,360.00 General
Category: CARDIOVASCULAR
06/01/2023 Merck Sharp & Dohme LLC Consulting Fee Cash or cash equivalent $5,995.00 General
04/19/2023 Merck Sharp & Dohme LLC Food and Beverage In-kind items and services $64.88 General
04/19/2023 Merck Sharp & Dohme LLC Food and Beverage In-kind items and services $59.47 General
04/19/2023 Merck Sharp & Dohme LLC Food and Beverage In-kind items and services $54.06 General
04/18/2023 Merck Sharp & Dohme LLC Travel and Lodging In-kind items and services $341.39 General
04/18/2023 Merck Sharp & Dohme LLC Travel and Lodging In-kind items and services $253.57 General
04/18/2023 Merck Sharp & Dohme LLC Travel and Lodging In-kind items and services $190.97 General
04/18/2023 Merck Sharp & Dohme LLC Food and Beverage In-kind items and services $148.68 General
04/18/2023 Merck Sharp & Dohme LLC Travel and Lodging In-kind items and services $111.35 General
07/17/2020 Bayer HealthCare Pharmaceuticals Inc. Adempas (Drug) Consulting Fee Cash or cash equivalent $1,290.00 General
Category: Cardio-pulmonary
11/21/2019 Janssen Research & Development, LLC OPSUMIT (Drug) Consulting Fee Cash or cash equivalent $1,500.00 General
Category: CARDIOVASCULAR DISORDERS
09/09/2019 Actelion Pharmaceuticals, Ltd Travel and Lodging Cash or cash equivalent $156.30 General
09/09/2019 Actelion Pharmaceuticals, Ltd Food and Beverage In-kind items and services $45.45 General
09/09/2019 Actelion Pharmaceuticals, Ltd Food and Beverage In-kind items and services $21.62 General
09/09/2019 Actelion Pharmaceuticals, Ltd Food and Beverage In-kind items and services $8.87 General
09/08/2019 Actelion Pharmaceuticals, Ltd Travel and Lodging Cash or cash equivalent $10,988.90 General
08/08/2019 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $600.00 General
11/28/2018 Actelion Clinical Research, Inc. Consulting Fee Cash or cash equivalent $600.00 General
05/29/2018 Bayer HealthCare Pharmaceuticals Inc. Adempas (Drug) Consulting Fee Cash or cash equivalent $3,440.00 General
Category: Cardio-pulmonary

About Dr. David Ivy, MD

Dr. David Ivy, MD is a Pediatric Cardiology healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083799712.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Ivy, MD has received a total of $44,137 in payments from pharmaceutical and medical device companies, with $6,564 received in 2024. These payments were reported across 41 transactions from 7 companies. The most common payment nature is "Travel and Lodging" ($22,935).

Practice Information

  • Specialty Pediatric Cardiology
  • Location Aurora, CO
  • Active Since 10/25/2006
  • Last Updated 03/25/2019
  • Taxonomy Code 2080P0202X
  • Entity Type Individual
  • NPI Number 1083799712

Products in Payments

  • Adempas (Drug) $14,586
  • WINREVAIR (Biological) $6,540
  • OPSUMIT (Drug) $1,500
  • ORENITRAM (Drug) $297.42
  • UPTRAVI (Drug) $23.59

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Cardiology Doctors in Aurora